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Objective: Stereotactic body radiotherapy (SBRT) is increasingly used to treat a variety
of tumors, including head and neck squamous cell carcinoma (HNSCC) in the recurrent
setting. While there are published data for re-irradiation using SBRT for HNSCC, there are
limited data supporting its use as upfront treatment for locally advanced disease.
Study Design/Methods: Here, we describe three patients who received SBRT as the pri-
mary treatment for their HNSCC along with a review of the current literature and discussion
of future pathways.
Results: The three cases discussed tolerated treatment well with manageable acute
toxicities and had either a clinical or radiographic complete response to therapy.
Conclusion: Head and neck squamous cell carcinoma presents a unique challenge in the
elderly, where medical comorbidities make it difficult to tolerate conventional radiation,
often given with a systemic sensitizer. For these individuals, providing a shortened course
using SBRT may offer an effective alternative.
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INTRODUCTION
The annual incidence of head and neck squamous cell carcinoma
(HNSCC) in the United States is estimated to be around 40,000
(1). While the majority of HNSCC cases occur in the fifth and sixth
decade of life, nearly one quarter of patients are older than 70 years
of age (2). These tumors predominantly involve the oral cavity and
oropharynx with the incidence of both increasing in the United
States and worldwide due to the human papillomavirus (HPV) (3,
4). While age may not specifically predict worse disease-specific
survival for head and neck cancer patients, the presence of multiple
medical comorbidities is known to decrease overall survival rates
for these patients (5). HNSCC treatment continues to be a multi-
disciplinary approach using surgery, chemotherapy, and radiation.
While surgery may be an option for some early stage head and neck
tumors, the morbidity associated with prolonged surgeries and/or
the post-operative functional or physical deformities can be quite
detrimental in the elderly (6). Patients with more advanced stage
cancers or those not amenable to surgery would typically receive
radiation with or without chemotherapy (7–9). Because toxicity
is higher with the addition of chemotherapy, combined modality
therapy in patients with multiple medical illnesses places them at
higher risk of treatment intolerance, which may lead to hospital-
izations and treatment interruptions (10). The most commonly
used radiation treatment regimen in elderly patients continues
to be conventional fractionation of 180–200 cGy per fraction to a
total dose of 7000 cGy. Several studies have demonstrated radiation
treatment to be quite tolerable in the elderly population with high
performance scores (11, 12). When treating elderly patients with
multiple comorbidities or dementia, however, life expectancy and
performance status along with social issues become important
factors that must be weighed into the treatment decision making
process.
Given the difficulty of standard HNSCC radiation treatment
in elderly individuals with poor performance scores, other treat-
ment options should be considered. Stereotactic body radiother-
apy (SBRT) provides an alternative approach for selected patients.
This technique can be effective, convenient, and tolerable so long
as normal tissue tolerance guidelines are adhered to patients (13).
SBRT relies on three fundamental principles: (1) precise, repro-
ducible stereotactic localization of the tumor (either using internal
or external references); (2) daily image guidance for tumor re-
localization as well as visualization of critical normal organs; and
(3) delivered treatment in 1–5 fractions (14). Fractionated SBRT
allows for delivery of highly conformal treatment of targets that
are in close proximity to critical structures. Fractionation has been
hypothesized to improve the therapeutic ratio, thereby reducing
the risk of late complications potentially associated with a large sin-
gle dose (15). The use of non-homogeneity to selectively vary the
dose at different sites within the target is another added benefit of
hypofractionated radiosurgery as it provides the flexibility to steer
a hot spot to the desired target and away from critical structures
such as the mandible while treating previously irradiated parotid

























































Amini et al. SBRT as therapy for head and neck cancer
tumors (15). In other words, a steeper dose gradient is constructed
to answer the clinical need. For these reasons, SBRT may be ben-
eficial in elderly patients with multiple comorbidities who would
not otherwise tolerate conventional fractionation for head and
neck tumors. Here, we present three cases of elderly patients with




Our first case was an 82-year-old man with multiple medical
comorbidities including severe dementia, chronic obstructive pul-
monary disease, and type II diabetes, who presented with an
enlarging, exophytic mass extending from his lip. He was a former
Table 1 | Patient and treatment characteristics.
Characteristics Case #1 Case #2 Case #3
Age 82 72 88





















None Grade 1 mucositis,
Grade 1 dermatitis,
Grade 2 dysphagia
CR, complete response; PR, partial response; LN, lymph node.
50 pack year smoker with a long history of daily chewing tobacco
use. The lesion presented 6 months prior and homeopathic reme-
dies were attempted prior to presenting to the clinic. On exam,
he had a fungating lesion over 40 mm in size involving the central
lower lip, sparing the bilateral commissures. The mass extended
from the buccal mucosa with no obvious bony involvement. A
computed tomography (CT) scan and magnetic resonance imag-
ing (MRI) of the head and neck demonstrated a 37 mm exophytic
mass, arising from the midline and left paramedian inner, lower
lip with no underlying bony involvement. Biopsy of the mass was
positive for ulcerated, invasive, well-differentiated squamous cell
carcinoma. It was not tested for HPV. He was staged as T2N0M0
(stage III). He was initially evaluated for a surgical resection and
reconstruction expected to last 12 h, but given the high periop-
erative risks involved, he was determined not to be a surgical
candidate. He was therefore referred to radiation oncology for
treatment.
Radiation treatment options were discussed, including inten-
sity modulated radiation treatment (IMRT) given over 6–7 weeks
covering his primary and draining lymphatics, versus localized
SBRT in five treatments. The patient and his family opted to pro-
ceed with SBRT and he received 3000 cGy in five twice-weekly
treatments (600 cGy per treatment), with concurrent cetuximab
(a loading dose of 400 mg/m2 preceding SBRT followed by six
weekly infusions of 250 mg/m2). The treatment field included
the lower lip and buccal mucosa (Figure 1). During treatment,
he had noticeable clinical response (Figures 2A,B). He tolerated
treatment well with the only adverse effects being grade 2 der-
matitis at the treatment site and grade 1 fatigue. He was seen at
2 months follow-up and had a marked improvement in tumor
volume and complete resolution of the treatment-related skin
erythema (Figure 2C). He had no oral functional deficits after
radiation treatment and was satisfied with the cosmetic outcomes.
At the time of manuscript submission, he was 12 months out from
treatment with continued response and no evidence of toxicity.
CASE 2
Our second case was a 72-year-old man with multiple comorbidi-
ties who initially presented to his primary care physician after his
FIGURE 1 | SBRT dose plan for our patient with squamous cell carcinoma of the lower lip demonstrated by an axial (A) and coronal (B) view. The
prescribed treatment dose of 3000 cGy is demonstrated in green.

























































Amini et al. SBRT as therapy for head and neck cancer
FIGURE 2 | Our patient with squamous cell carcinoma involving the lower lip, before treatment (A), 15days (B), and 74days (C) post-treatment.
wife noticed an enlarging, painful left neck mass. His past medical
history was significant for severe dementia requiring hospitaliza-
tions, bradycardia requiring a pacemaker, carotid artery disease,
and hypertension. He was a non-smoker who drank alcohol occa-
sionally. Imaging that included a CT scan identified an enlarging
left cervical lymph node with central necrosis, measuring 3 cm.
Fine needle aspiration (FNA) of the lymph node was positive for
squamous cell carcinoma (HPV testing not performed). Flexible
nasopharyngoscopy could not identify the primary site of dis-
ease. A follow-up PET scan again identified a 33 mm× 30 mm left
level II lymph node, standardized uptake value (SUV) 12.5, and a
25 mm× 13 mm right level II lymph node, SUV 4.3. There were
no other areas of FDG avidity. He was staged cT0N2cM0 (stage
IVA) and was referred to radiation oncology to discuss treatment
options. At the time of presentation, he was in an acute rehabilita-
tion facility for progressive dementia and antibiotics for a recent
bacteremia.
Given his severe dementia, it was concluded he would not toler-
ate standard head and neck treatment. Further workup, including
directed biopsies and tonsillectomy, was also declined given his
high perioperative risks. Therefore, he was treated with SBRT
to 2500 cGy in five treatments given daily (500 cGy per treat-
ment), with no concurrent systemic sensitizer. The treatment field
included the enlarging left cervical lymph node encompassing
levels II/III, which was limiting his head movements. During treat-
ment, he had some response in the left neck with resolution of the
palpable lymph node. He did not develop any notable toxicity
from treatment, including dermatitis, mucositis, or esophagitis.
The plan was to return and treat the right cervical lymph node
as well, however, his dementia rapidly progressed following treat-
ment and he soon entered hospice care. He passed away 8 months
after completing treatment from causes unrelated to his cancer. At
that time, he had no clinical evidence of disease at the treated left
cervical node.
CASE 3
Our third case was an 88-year-old woman who presented with a
painful left neck mass for 1 month with associated weight loss. She
was a non-smoker with no significant past medical history. PET
scan identified a large hypermetabolic left cervical lymph node,
measuring 44 mm× 29 mm (SUV 12.2), a 9 mm left cervical node
(SUV 7.0) with asymmetry at the left base of tongue. Incidentally, a
hypermetabolic 15 mm left breast lesion was also found, along with
left axillary and subpectoral lymphadenopathy. There was also
FDG avidity involving the fifth lumbar (L5) vertebral body, with an
associated destructive lesion. FNA of the left cervical mass was pos-
itive for squamous cell carcinoma, HPV positive by p16 staining.
Breast biopsy was consistent with intraductal carcinoma (ER/PR
positive, HER2/neu negative) and she was staged T1cN1M0 (stage
IIA). Biopsy of the L5 lesion was consistent with poorly differen-
tiated carcinoma, pathologically similar to the biopsied cervical
lymph node. She was staged as cT1N2bM1 (stage IVC), base of
tongue primary.
Given the systemic involvement of her HNSCC, her concur-
rent breast cancer, and patient refusal for a prolonged course of
radiation treatment, SBRT was offered for local and symptomatic
control. She underwent radiation treatment with SBRT, treated
to 3600 cGy in five twice-weekly treatments (720 cGy per treat-
ment) to gross disease including base of tongue and 3000 cGy in
five twice-weekly treatments (600 cGy per treatment) to ipsilateral,
uninvolved draining lymph nodes. During treatment, she devel-
oped some initial mild left neck swelling which quickly resolved.
She also experienced grade 1 mucositis, grade 1 dermatitis, oral
thrush, and grade 2 dysphagia toward the end of treatment. Fol-
lowing completion of treatment to her head and neck, her L5
vertebral body was treated with SBRT, 2700 cGy in three twice-
weekly treatments (900 cGy per treatment). She elected to not
receive any treatment for her breast cancer. At 4 month follow-up,
her treatment-related side effects had resolved and she clinically
had no evidence of disease in her head and neck, though multiple
new hypermetabolic lesions were found in the right femoral neck,
gastric fundus, and right hepatic lobe. These were not biopsied
to differentiate between metastatic head and neck versus metasta-
tic breast cancer. She received palliative treatment to her right
femur and L4-S1 vertebral bodies, 2000 cGy in five treatments
given every other day (400 cGy per treatment). Repeat PET scan
at 6 months showed further progression of disease including mul-
tiple new liver lesions, bone lesions involving the spine and ribs,
pancreatic mass, and peritoneal carcinomatosis. The left cervical
lymph node conglomeration had decreased in size and FDG avid-
ity, and no evidence of disease was observed at the left base of
tongue. The patient passed away 8 months after original diagnosis
due to her metastatic disease.
DISCUSSION
For elderly patients with HNSCC or in younger patients with poor
performance status, proper assessment of their medical conditions
is critical in the initial workup. While elderly patients with good
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performance status should receive standard of care (12), those
with multiple comorbidities who cannot tolerate standard ther-
apy may benefit from a shortened, local consolidative treatment
approach. Although definitive chemoradiation is associated with
improved overall survival benefit (9), it comes at a price of sub-
stantial morbidity in a patient population with baseline multiple
medical comorbidities due to the often long-term use of tobacco
and excessive alcohol consumption (10, 16–18). This may suggest
why some elderly patients perhaps have less benefit to treatment
(9), as they present with multiple medical issues, which can lead
to poorer treatment compliance (10, 18).
Currently, there is growing literature supporting the use of both
conventional hypofractionated external beam radiotherapy and
higher dose per fraction SBRT for primary or recurrent head and
neck treatment in patients who are inoperable and cannot tol-
erate conventional fractionation (19, 20). Two small Australian
studies evaluated hypofractionated palliative radiation as primary
treatment for incurable or medically unsuitable patients. The first,
“QUAD SHOT,”consisted of 1400 cGy in four fractions given twice
a day for two days and then repeated up to two more times at
4-week intervals if no tumor progression occurred. In all, 53%
had an objective response and 23% had stable disease with over-
all survival of 5.7 months (21). The other study, “Hypo-Trial,”
gave 3000 cGy in five fractions at two fractions/week. The over-
all objective response rate was 80% and median time to death was
6.1 months (22). Both studies prospectively assessed quality of life
during treatment [using either the EORTC QLQ-C30 or Func-
tional Assessment of Cancer Therapy (FACT) methods], and both
showed improvement in quality of life parameters. In addition, a
number of studies published have reported outcomes with SBRT
in both the upfront and recurrent setting (Table 2). A small, ret-
rospective series recently published from Japan (23) reviewed 14
elderly patients who received primary SBRT without a sensitizer
for the initial management of their head and neck cancers. Radi-
ation doses ranged from 3500 to 4200 cGy, given in 3–5 fractions.
At a mean follow-up of 3 years, local control and overall survival
were 71.4 and 78.6%, respectively. Toxicities were mostly grade 1
or 2 with one grade 3 osteonecrosis in a patient who received a sec-
ond treatment of SBRT following disease recurrence. Similarly, in
another retrospective analysis of elderly patients treated with pri-
mary SBRT for salivary gland tumors, Karam et al. showed 2-year
local control rate of 84% at a median follow-up of 14 months (24).
The treatment was also reportedly well tolerated with no grade 4
toxicities. Lastly, a series evaluating recurrent nasopharyngeal car-
cinoma also demonstrated favorable outcomes in the SBRT group
when compared to conventional fractionation (25).
Stereotactic body radiotherapy also represents a more conve-
nient and cost-effective approach of treating elderly patients with
poor performance status. At times in our experience, patients must
travel long distances and it may be a burden financially for these
patients. Some elderly patients at our center have to travel long
distances for treatment and may not have the social support or
financial means to stay away from home for 6–7 weeks and simply
refuse treatment if it cannot be offered over a shorter time period.
In fact, we have also encountered this situation in Colorado with
patients less than 70 years of age with excellent performance sta-
tus. SBRT offers a rapid and precise alternative strategy for these
individuals with poor prognostic scores and locoregionally con-
fined disease through the use of improved imaging modalities,
implementation of sophisticated planning, and delivery systems
with daily image guidance (27). Lastly, when evaluating radiation
treatment modalities used in other disease sites, SBRT has been
shown to be very cost-effective (28–30).
Radiobiologically, the higher dose per fraction with SBRT-
based treatments has been shown to provide improved local con-
trol over standard fractionation. As the survival and proliferation
of tumor cells are directly dependent on the blood supply, SBRT
has been shown to have a direct effect on tumor vasculature. High-
dose radiation with 10 Gy or higher in a single fraction has been
shown to cause severe vascular damage in human tumor xenografts
or animal tumors (31, 32). Additionally, the vascular injury and
ensuing chaotic intratumor environment, such as hypoxic, acidic,











Median PFS Median OS
Heron et al. (13) Prospective 25 Recurrent 25–44 Gy total in 5
fractions over 2 weeks
N/a 4 mo 6 mo
Roh et al. (19) Retrospective 36 Recurrent 18–40 Gy in 3–5
fractions
N/a 61% at 12 mo 16.2 mo
Siddiqui et al. (20) Retrospective 44 Both Range of single fraction
13–18 Gy or 36–48 Gy in
5–8 fractions










71.4% at 36 mo 78.6% at 36 mo
Rwigema et al. (26) Retrospective 85 Recurrent Median dose 35 Gy in
fraction sizes of 4–18Gy
N/a 5.5 mo 11.5 mo
PFS, progression free survival, OS, overall survival, mo: months.
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and nutritionally deprived environment caused by high-dose frac-
tion SBRT, may significantly hinder the repair of radiation damage
(33). However, one must still remain cognizant of neighboring
critical structures and as such,our patients did not receive fractions
of 10 Gy or higher.
Dose constraints in the setting of primary SBRT for head and
neck cancer are extrapolated from the head and neck re-irradiation
literature and from other systems as data for constraints in the
primary setting are lacking. In lieu of this, we have attempted to
draw from the Quantitative Analysis of Normal Tissue Effects in
the Clinic (QUANTEC), head/neck re-irradiation literature and
clinical studies to help guide individuals interested in pursuing
head/neck SBRT. In the primary setting, spinal cord SBRT dose
constraints are the most studied and documented. Per published
QUANTEC guidelines, spinal SBRT partial cord irradiation max
dose constraints is reported at 13 Gy for single fraction treatment
and 20 Gy for three fractions treatment is thought to be associated
with<1% risk for myelopathy (34). Based on our own institutional
experience combined with Dr. Timmerman at UT Southwestern,
constraints for five fractions are more generous allowing for a max
point of 28 Gy and V22< 10% assuming 5–6 mm above and below
the spinal cord subvolume being treated (unpublished data). Typi-
cal re-irradiation dose constraints derived from the Pittsburgh and
Georgetown series (26, 35) tend to be more conservative (spinal
max point≤ 8 Gy in one fraction and≤ 12 Gy in two fractions)
but again, these are based on re-irradiation SBRT compared to the
established 10 Gy to 10% of partial spinal cord being irradiated in
the upfront setting (36). Similarly for brainstem, Dmax < 12.5 Gy
in a single fraction is predicted to be associated with <5% risk
for cranial neuropathy or necrosis (37). The NRG head and neck
committee is currently developing an SBRT trial for recurrent
HNC that will evaluate its efficacy and safety in combination with
immunomodulation using a PD-1 antibody.
In addition to the present limitations of current data on SBRT
toxicity for head and neck cancers as discussed, the first two cases
demonstrate the challenge of treating patients with dementia.
SBRT relies on reproducibility, which may be difficult to maintain
in patients who are unable to remain still. Additionally, patients
with dementia require redirecting and daily coaching in order
to tolerate and complete radiation therapy. Given the morbid-
ity associated with untreated head and neck cancers, however,
it is still reasonable to treat head and neck cancer patients with
dementia and as shown in the first two cases, a shortened course
of radiation may be better tolerated and more manageable than
a standard course of therapy. Ultimately, a lengthy discussion is
indicated between the radiation oncologist, patient, and family to
assess tolerability of treatment.
For other head and neck sites, our recommendations derive
from the re-irradiation literature and some prospective studies.
However, assuming SBRT in the primary setting, dose constraints
are likely to be more generous given lack of prior radiotherapy but
we would caution a more conservative approach combined with
clinician judgment in the absence of any prospective data.
CONCLUDING REMARKS
Management of elderly patients with HNSCC who present
with multiple comorbidities can pose a unique challenge. SBRT
therefore may be a viable option for elderly patients unable to
receive standard of care combined modality therapy. Of the avail-
able radiation treatments, however, SBRT has arguably the greatest
potential for benefit and harm due to the very high, ablative doses
of radiation used. This approach therefore warrants a prospec-
tive study and may be especially appropriate for well-lateralized
head and neck cancers. In addition, incorporation of biologically
based agents such as EGFR inhibitors, DNA repair inhibitors, or
immunomodulation may enhance local-regional effectiveness of
SBRT without a significant increase in acute toxicity.
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